BioSpace News Archive

Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces that Aniz Girach, MD, is joining the Board of directors as an independent Board member.

The online store’s newly restocked AirPhysio breathing device is recommended for those who suffer from COPD due to smoking and want to get rid of extra mucus and strengthen their lungs.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference.

Calibre Scientific is pleased to announce the acquisition of AmpliTech, a distributor of reagents and instruments to research and diagnostic laboratories with headquarters in Compiègne, France.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 12, 2022, at 10:30 a.m. ET

BioCryst Pharmaceuticals, Inc. today announced that the company will present at the 40th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Monday, January 10, 2022 at 9:45 a.m. ET.

Genocea Biosciences, Inc. has entered into an R&D collaboration and option agreement with Janssen Biotech, Inc., to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in the context of vaccine therapies for cancer.

Viridian Therapeutics, Inc. announced the submission of an investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for VRDN-002, a humanized monoclonal antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous injection for the treatment of thyroid eye disease (TED).

Plus Therapeutics, Inc. today announced it has met two significant milestones as it progresses toward cGMP manufacture of Rhenium-186 NanoLiposome (186RNL).

Cullinan Oncology, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Therapy Designation for CLN-081 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.